Imlifdase – a novel approach to eliminate pathogenic IgG
Imlifidase’s Mode of Action is that it cleaves IgG within 2-6 hours from a 15-minute infusion, IgG levels
will then drop to below detectable levels and stay supressed for approximately 5-7 days, before it gradually returns
back to normal levels.
Potential indication universe
Beyond kidney transplantation, imlifidase could potentially be used in post-transplantation and transplantation of
other organs, as a treatment for acute autoimmune diseases and as a pre-treatment for gene therapy.
Additionally, Hansa is developing a next generation of enzymes under the program NiceR for repeat dosing
administration. The NiceR program will potentially open a very large universe of potential indications, including a
number of gene therapy programs, autoimmune diseases and oncology.
Our Business Model
In transplantation and autoimmune diseases, Hansa Biopharma intends utilize its own commercial infrastructure,
utilizing inhouse capabilities from an experienced and skilled team to secure a successfully entry into these
markets. In other areas where the market overall is more complex and fragmented, such as gene therapy and oncology,
Hansa will consider alternative pathways for commercial success. In these markets, Hansa may employ a partnering
strategy similar to the agreement with Sarepta Therapeutics in gene therapy.
Our Strategic Priorities
Our development programs
Our antibody cleaving enzyme technology platform
Our mid-term financial priorities
Hansa’s key midterm financial priorities will be focused on securing a successful European launch as well as
commercially expand across larger European markets, while targeting satisfactory product profitability in Europe.
Secondly, the Company wish to further strengthen the position and expansion in kidney transplantation as Hansa
approach a potential market approval in the U.S.
Thirdly the Company anticipate accelerating its activities in areas such as autoimmunity, gene therapy and oncology.
Lastly, Hansa wish to continue to engage in more potential partnerships in both gene therapy and oncology as well as
into technology areas, where it potentially makes senses to build develop combination therapies.